 HOUSTON, Jan. 13, 2021 GLOBE NEWSWIRE -- Salarius Pharmaceuticals, Inc. Nasdaq: SLRX, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a 0.9 million payment as the second installment of 1.7 million in scheduled payments to Salarius under its contract with the Cancer Prevention and Research Institute of Texas CPRIT. The payments, which include the previously announced receipt of an 0.8 million disbursement announced on December 10, 2020, are part of an original non-dilutive grant awarded in 2016 to support Salarius operations and development of its lead drug candidate, seclidemstat, for the treatment of Ewing sarcoma and other cancers. Seclidemstat is a reversible LSD1 inhibitor being studied in two clinical trials one trial in relapsedrefractory Ewing sarcoma, a rare and deadly pediatric bone and soft tissue cancer, and a second trial in advanced solid tumors AST. Up to 4.8 million in funding remains available to Salarius under the original 2016 CPRIT Award. 